查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1750862

预测性生物标记市场规模、份额、趋势分析报告：适应症、技术、地区、细分市场预测，2025-2030

Predictive Biomarkers Market Size, Share & Trends Analysis Report By Indication, By Technology (Diagnostics, Drug Discovery & Development, Personalized Medicine, Disease Risk Assessment), By Region, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10个工作天内

价格

预测性生物标记市场摘要

预计 2024 年全球预测生物标记市场规模为 243 亿美元，到 2030 年将达到 635.4 亿美元，2025 年至 2030 年的复合年增长率为 18.02%。由于基因组学和精准医疗的进步、研发投资的增加以及对早期检测和个人化治疗的需求不断增长等多种因素，该市场正在经历显着增长。

研发是预测性生物标记市场成长的主要驱动力，它促进了创新和新候选生物标记的发现。基因组学和精准医疗处于医疗技术的前沿，为更有针对性和更有效的治疗提供了潜力。干预效果的预测性生物标记可以反映个体的生物成分（「宿主特征」），或与疾病过程和其他病理相关的特征。英国国家医疗服务体系 (NHS) 和政府正在大力投资这些技术，包括推出 NHS 基因组医学服务。该服务致力于推动基因组学发展，造福患者，包括进行基因组序列测定、为癌症患者提供分子诊断和基因检测，以及增强数据整合以推动更有效的治疗。此外，透过合作，我们累积了技术和数据分析的专业知识，并在开发新型定序技术方面拥有深厚的专业知识，这些专业知识能够推动创新和有效治疗。

例如，2025年4月，Ilmunia与Tempus AI合作，加速向患者推出次世代定序检测。

研发投入的增加是预测性生物标记市场的主要驱动力。製药公司、生技公司和学术机构正投入大量资源来发现新的生物标记并推动诊断技术的发展。生物标记辨识的主要应用之一是次世代定序仪(NGS)，它可以快速检测基因内数百万个 DNA 拷贝。该技术能够在短时间内对多个基因和突变进行全面分析。例如，Illumina 的 NovaSeq X 平台提供高通量定序，用于数据分析和疾病诊断。生物标记发现领域的资金投入和合作不断增加，促进了更有效、更准确的预测测试的发展。这正在加速预测性生物标记市场的成长，并支持下一代医疗保健创新。

对疾病早期检测和个人化治疗的需求不断增长，是预测性生物标记市场的主要驱动力之一。生物标记能够提供关于个人健康状况的宝贵见解，并有助于在症状出现之前的早期识别疾病。早期检测可以实现更有效的干预，改善患者预后并降低治疗成本。预测性生物标记的一个关键应用领域是肿瘤学，其中抗治疗性的迹象（这仍然是乳癌患者死亡的主要驱动因素）推动了对预测性生物标记开发的需求。

人们正在研究体学技术和人工智慧等创新方法，以识别高度精准的分子和成像生物标记物，从而有可能改善治疗效果。生物标记物正越来越普遍地被纳入临床试验，用于安全性和有效性研究。预测性生物标记物也可能成为临床试验的一部分，以根据患者需求客製化药物。随着医疗保健系统向个人化医疗转变，预测性生物标记将在优化治疗方法和确保每位患者获得正确治疗方面发挥关键作用。

目录

第一章调查方法与范围

第二章执行摘要

3. 预测性生物标记市场变数、趋势和范围

  • 市场展望
    • 母市场展望
    • 相关/附随市场展望
  • 市场动态
    • 市场驱动因素分析
    • 市场限制因素分析
  • 预测生物标誌物市场分析工具
    • 产业分析-波特五力分析
    • PESTEL分析

第四章预测生物标记市场：适应症估计与趋势分析

  • 细分仪表板
  • 预测性生物标记市场：变异分析
  • 预测生物标记市场规模和趋势分析（2018-2030）
  • 预测生物标记市场收益估计和预测（2018-2030）
  • 癌症
  • 心血管疾病
  • 神经系统疾病
  • 免疫疾病
  • 其他的

第五章预测生物标记市场：技术评估与趋势分析

  • 2024年及2030年的市场占有率
  • 细分仪表板
  • 全球预测生物标誌物市场前景
  • 市场规模、预测与趋势分析（2018-2030年）
  • 诊断
  • 药物研发
  • 个人化医疗
  • 疾病风险评估
  • 其他的

第六章预测生物标记市场：区域估计与趋势分析

  • 2024 年及 2030 年区域市场占有率分析
  • 区域市场仪表板
  • 全球区域市场概况
  • 市场规模、预测趋势分析，2018 年至 2030 年：
  • 北美洲
    • 北美：SWOT分析
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 欧洲：SWOT分析
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 挪威
    • 瑞典
    • 丹麦
  • 亚太地区
    • 亚太地区：SWOT分析
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 韩国
    • 泰国
  • 拉丁美洲
    • 拉丁美洲：SWOT分析
    • 巴西
    • 阿根廷
  • 中东和非洲
    • MEA：SWOT分析
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 科威特

第七章 竞争态势

  • 主要市场参与企业的近期趋势和影响分析
  • 公司/竞争对手分类
  • 供应商格局
    • 主要经销商和通路合作伙伴名单
    • 主要客户
    • 主要企业市场占有率分析（2024年）
    • Thermo Fisher Scientific Inc.
    • Qiagen
    • F. Hoffmann-La Roche Ltd
    • Bio-Rad Laboratories, Inc
    • Agilent Technologies, Inc.
    • Illumina Inc.
    • Merck KGaA
    • Bio-Techne
    • Siemens Healthineers AG
    • PerkinElmer
    • Myriad Genetics, Inc.
    • Becton Dickinson
    • Danaher Corporation
    • Genomic Health, Inc.
    • PacBio
Product Code: GVR-4-68040-593-9

Predictive Biomarkers Market Summary

The global predictive biomarkers market size was estimated at USD 24.30 billion in 2024 and is projected to reach USD 63.54 billion by 2030, growing at a CAGR of 18.02% from 2025 to 2030. The market is experiencing significant growth driven by several factors such as advancements in genomics and precision medicines, increased investment in research and development and rising demand for early detection and personalized treatments.

Research and development (R&D) is a major driver of growth in the predictive biomarkers market, fueling innovation and the discovery of new biomarker candidates. Genomics and precision medicine are at the forefront of medical technology, offering the potential for more targeted and effective treatments. Predictive biomarkers for the effects of interventions can reflect an individual's biological constituents ("host characteristics") or traits associated with the disease process or other medical conditions. The NHS and the government are making significant investments in these technologies, including the launch of the NHS Genomic Medicine Service. This service is dedicated to advancements in genomics to benefit patients by implementing genome sequencing, providing molecular diagnostics and genetic testing for cancer patients, and enhancing data integration to facilitate more effective treatments. Moreover, expertise in technology and data analytics with proficiency in developing new sequencing technologies, is

achieved through collaborations that drive innovation and advance precision medicine for instance, in April 2025, Illumnia collaborated with Tempus AI to accelerate adoption of next generation sequencing tests for patients.

The growing investment in research and development (R&D) is a key driver of the predictive biomarkers market. Pharmaceutical companies, biotech firms, and academic institutions are dedicating significant resources to discovering new biomarkers and advancing diagnostic technologies. One prominent application for biomarker identification is next-generation sequencing (NGS), which can rapidly detect millions of DNA copies within a gene. This technology enables comprehensive profiling of multiple genes and mutations in a short amount of time. For example, Illumina's NovaSeq X platform offers high-throughput sequencing for analyzing large sequences of data and diagnose the condition of disease. The increasing funding and collaborative efforts in biomarker discovery lead to the development of more effective and accurate predictive tests. This, in turn, is accelerating the growth of the predictive biomarkers market, supporting the next generation of healthcare innovations.

There is an increasing demand for early disease detection and personalized treatments, which is one of the key driver in predictive biomarkers market. Biomarkers provide valuable insights into an individual's health, helping identify diseases in their early stages before symptoms appear. Early detection enables more effective interventions, improving patient outcomes and reducing treatment costs. An important application of predictive biomarkers is in oncology, which demonstrates resistance to treatment that continues to be a leading cause of mortality in breast cancer patients, driving the need for the development of predictive biomarkers.

Innovative approaches, such as omics technologies and artificial intelligence, are being explored to identify highly accurate molecular or imaging biomarkers, with the potential to enhance treatment outcomes. Biomarkers are even gaining popularity incorporation into clinical trials for safety and efficacy tests. Predictive biomarkers may also become a part of these trials tailoring of medicines according to patient needs. As healthcare systems shift toward individualized medicine, predictive biomarkers play a crucial role in optimizing treatment regimens and ensuring the right therapy for each patient.

Global Predictive Biomarkers Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For the purpose of this study, Grand View Research has segmented the global predictive biomarkers market report on the basis of indication, technology and region.

  • Indication Outlook (Revenue, USD Million, 2018 - 2030)
  • Cancer
  • Cardiovascular Diseases
  • Neurological Diseases
  • Immunological Diseases
  • Others
  • Technology Outlook (Revenue, USD Million, 2018 - 2030)
  • Diagnostics
  • Drug Discovery & Development
  • Personalized Medicine
  • Disease Risk Assessment
  • Others
  • Regional Outlook (Revenue in USD Million, 2018 - 2030)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Sweden
    • Denmark
    • Norway
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Thailand
  • Latin America
    • Brazil
    • Argentina
  • Middle East and Africa
    • Saudi Arabia
    • South Africa
    • UAE
    • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Indication
    • 1.2.2. Technology
    • 1.2.3. Regional scope
    • 1.2.4. Estimates and forecasts timeline.
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Indication outlook
    • 2.2.2. Technology outlook
    • 2.2.3. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Predictive Biomarkers Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook.
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
    • 3.2.2. Market restraint analysis
  • 3.3. Predictive Biomarkers Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
    • 3.3.2. PESTEL Analysis

Chapter 4. Predictive Biomarkers Market: Indication Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Predictive Biomarkers Market: Indication Movement Analysis
  • 4.3. Predictive Biomarkers Market Size & Trend Analysis, by indication, 2018 to 2030 (USD Million)
  • 4.4. Predictive Biomarkers Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.5. Cancer
    • 4.5.1. Cancer Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.6. Cardiovascular Diseases
    • 4.6.1. Cardiovascular Diseases Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.7. Neurological Diseases
    • 4.7.1. Neurological Diseases Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.8. Immunological Diseases
    • 4.8.1. Immunological Diseases Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.9. Others
    • 4.9.1. Others Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Predictive Biomarkers Market: Technology Estimates & Trend Analysis

  • 5.1. Technology Market Share, 2024 & 2030
  • 5.2. Segment Dashboard
  • 5.3. Global Predictive Biomarkers Market by Technology Outlook
  • 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 5.5. Diagnostics
    • 5.5.1. Diagnostics Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.6. Drug Discovery & Development
    • 5.6.1. Drug Discovery & Development Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.7. Personalized Medicine
    • 5.7.1. Personalized Medicine Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.8. Disease Risk Assessment
    • 5.8.1. Disease Risk Assessment Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.9. Others
    • 5.9.1. Others Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Predictive Biomarkers Market: Regional Estimates & Trend Analysis

  • 6.1. Regional Market Share Analysis, 2024 & 2030
  • 6.2. Regional Market Dashboard
  • 6.3. Global Regional Market Snapshot
  • 6.4. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 6.5. North America
    • 6.5.1. North America: SWOT Analysis
    • 6.5.2. U.S.
      • 6.5.2.1. Key country dynamics
      • 6.5.2.2. Regulatory framework/Reimbursement
      • 6.5.2.3. Competitive scenario
      • 6.5.2.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.5.3. Canada
      • 6.5.3.1. Key country dynamics
      • 6.5.3.2. Regulatory framework/Reimbursement
      • 6.5.3.3. Competitive scenario
      • 6.5.3.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.5.4. Mexico
      • 6.5.4.1. Key country dynamics
      • 6.5.4.2. Regulatory framework/Reimbursement
      • 6.5.4.3. Competitive scenario
      • 6.5.4.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6. Europe
    • 6.6.1. Europe: SWOT Analysis
    • 6.6.2. UK
      • 6.6.2.1. Key country dynamics
      • 6.6.2.2. Regulatory framework/Reimbursement
      • 6.6.2.3. Competitive scenario
      • 6.6.2.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.6.3. Germany
      • 6.6.3.1. Key country dynamics
      • 6.6.3.2. Regulatory framework/Reimbursement
      • 6.6.3.3. Competitive scenario
      • 6.6.3.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.6.4. France
      • 6.6.4.1. Key country dynamics
      • 6.6.4.2. Regulatory framework/Reimbursement
      • 6.6.4.3. Competitive scenario
      • 6.6.4.4. France market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.6.5. Italy
      • 6.6.5.1. Key country dynamics
      • 6.6.5.2. Regulatory framework/Reimbursement
      • 6.6.5.3. Competitive scenario
      • 6.6.5.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.6.6. Spain
      • 6.6.6.1. Key country dynamics
      • 6.6.6.2. Regulatory framework/Reimbursement
      • 6.6.6.3. Competitive scenario
      • 6.6.6.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.6.7. Norway
      • 6.6.7.1. Key country dynamics
      • 6.6.7.2. Regulatory framework/Reimbursement
      • 6.6.7.3. Competitive scenario
      • 6.6.7.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.6.8. Sweden
      • 6.6.8.1. Key country dynamics
      • 6.6.8.2. Regulatory framework/Reimbursement
      • 6.6.8.3. Competitive scenario
      • 6.6.8.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.6.9. Denmark
      • 6.6.9.1. Key country dynamics
      • 6.6.9.2. Regulatory framework/Reimbursement
      • 6.6.9.3. Competitive scenario
      • 6.6.9.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.7. Asia Pacific
    • 6.7.1. Asia Pacific: SWOT Analysis
    • 6.7.2. Japan
      • 6.7.2.1. Key country dynamics
      • 6.7.2.2. Regulatory framework/Reimbursement
      • 6.7.2.3. Competitive scenario
      • 6.7.2.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.7.3. China
      • 6.7.3.1. Key country dynamics
      • 6.7.3.2. Regulatory framework/Reimbursement
      • 6.7.3.3. Competitive scenario
      • 6.7.3.4. China market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.7.4. India
      • 6.7.4.1. Key country dynamics
      • 6.7.4.2. Regulatory framework/Reimbursement
      • 6.7.4.3. Competitive scenario
      • 6.7.4.4. India market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.7.5. Australia
      • 6.7.5.1. Key country dynamics
      • 6.7.5.2. Regulatory framework/Reimbursement
      • 6.7.5.3. Competitive scenario
      • 6.7.5.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.7.6. South Korea
      • 6.7.6.1. Key country dynamics
      • 6.7.6.2. Regulatory framework/Reimbursement
      • 6.7.6.3. Competitive scenario
      • 6.7.6.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.7.7. Thailand
      • 6.7.7.1. Key country dynamics
      • 6.7.7.2. Regulatory framework/Reimbursement
      • 6.7.7.3. Competitive scenario
      • 6.7.7.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.8. Latin America
    • 6.8.1. Latin America: SWOT Analysis
    • 6.8.2. Brazil
      • 6.8.2.1. Key country dynamics
      • 6.8.2.2. Regulatory framework/Reimbursement
      • 6.8.2.3. Competitive scenario
      • 6.8.2.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.8.3. Argentina
      • 6.8.3.1. Key country dynamics
      • 6.8.3.2. Regulatory framework/Reimbursement
      • 6.8.3.3. Competitive scenario
      • 6.8.3.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.9. MEA
    • 6.9.1. MEA: SWOT Analysis
    • 6.9.2. South Africa
      • 6.9.2.1. Key country dynamics
      • 6.9.2.2. Regulatory framework/Reimbursement
      • 6.9.2.3. Competitive scenario
      • 6.9.2.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.9.3. Saudi Arabia
      • 6.9.3.1. Key country dynamics
      • 6.9.3.2. Regulatory framework/Reimbursement
      • 6.9.3.3. Competitive scenario
      • 6.9.3.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.9.4. UAE
      • 6.9.4.1. Key country dynamics
      • 6.9.4.2. Regulatory framework/Reimbursement
      • 6.9.4.3. Competitive scenario
      • 6.9.4.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.9.5. Kuwait
      • 6.9.5.1. Key country dynamics
      • 6.9.5.2. Regulatory framework
      • 6.9.5.3. Competitive scenario
      • 6.9.5.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 7.2. Company/Competition Categorization
  • 7.3. Vendor Landscape
    • 7.3.1. List of key distributors and channel partners
    • 7.3.2. Key customers
    • 7.3.3. Key company market share analysis, 2024
    • 7.3.4. Thermo Fisher Scientific Inc.
      • 7.3.4.1. Company overview
      • 7.3.4.2. Financial performance
      • 7.3.4.3. Services benchmarking
      • 7.3.4.4. Strategic initiatives
    • 7.3.5. Qiagen
      • 7.3.5.1. Company overview
      • 7.3.5.2. Financial performance
      • 7.3.5.3. Services benchmarking
      • 7.3.5.4. Strategic initiatives
    • 7.3.6. F. Hoffmann-La Roche Ltd
      • 7.3.6.1. Company overview
      • 7.3.6.2. Financial performance
      • 7.3.6.3. Services benchmarking
      • 7.3.6.4. Strategic initiatives
    • 7.3.7. Bio-Rad Laboratories, Inc
      • 7.3.7.1. Company overview
      • 7.3.7.2. Financial performance
      • 7.3.7.3. Services benchmarking
      • 7.3.7.4. Strategic initiatives
    • 7.3.8. Agilent Technologies, Inc.
      • 7.3.8.1. Company overview
      • 7.3.8.2. Financial performance
      • 7.3.8.3. Services benchmarking
      • 7.3.8.4. Strategic initiatives
    • 7.3.9. Illumina Inc.
      • 7.3.9.1. Company overview
      • 7.3.9.2. Financial performance
      • 7.3.9.3. Services benchmarking
      • 7.3.9.4. Strategic initiatives
    • 7.3.10. Merck KGaA
      • 7.3.10.1. Company overview
      • 7.3.10.2. Financial performance
      • 7.3.10.3. Services benchmarking
      • 7.3.10.4. Strategic initiatives
    • 7.3.11. Bio-Techne
      • 7.3.11.1. Company overview
      • 7.3.11.2. Financial performance
      • 7.3.11.3. Services benchmarking
      • 7.3.11.4. Strategic initiatives
    • 7.3.12. Siemens Healthineers AG
      • 7.3.12.1. Company overview
      • 7.3.12.2. Financial performance
      • 7.3.12.3. Services benchmarking
      • 7.3.12.4. Strategic initiatives
    • 7.3.13. PerkinElmer
      • 7.3.13.1. Company overview
      • 7.3.13.2. Financial performance
      • 7.3.13.3. Services benchmarking
      • 7.3.13.4. Strategic initiatives
    • 7.3.14. Myriad Genetics, Inc.
      • 7.3.14.1. Company overview
      • 7.3.14.2. Financial performance
      • 7.3.14.3. Services benchmarking
      • 7.3.14.4. Strategic initiatives
    • 7.3.15. Becton Dickinson
      • 7.3.15.1. Company overview
      • 7.3.15.2. Financial performance
      • 7.3.15.3. Services benchmarking
      • 7.3.15.4. Strategic initiatives
    • 7.3.16. Danaher Corporation
      • 7.3.16.1. Company overview
      • 7.3.16.2. Financial performance
      • 7.3.16.3. Services benchmarking
      • 7.3.16.4. Strategic initiatives
    • 7.3.17. Genomic Health, Inc.
      • 7.3.17.1. Company overview
      • 7.3.17.2. Financial performance
      • 7.3.17.3. Services benchmarking
      • 7.3.17.4. Strategic initiatives
    • 7.3.18. PacBio
      • 7.3.18.1. Company overview
      • 7.3.18.2. Financial performance
      • 7.3.18.3. Services benchmarking
      • 7.3.18.4. Strategic initiatives

List of Tables

  • Table 1 List of abbreviations
  • Table 2 North America Predictive biomarkers market, by region, 2018 - 2030 (USD Million)
  • Table 3 North America Predictive biomarkers market, by indication, 2018 - 2030 (USD Million)
  • Table 4 North America Predictive biomarkers market, by technology, 2018 - 2030 (USD Million)
  • Table 5 U.S Predictive biomarkers market, by indication, 2018 - 2030 (USD Million)
  • Table 6 U.S Predictive biomarkers market, by technology, 2018 - 2030 (USD Million)
  • Table 7 Canada Predictive biomarkers market, by indication, 2018 - 2030 (USD Million)
  • Table 8 Canada Predictive biomarkers market, by technology, 2018 - 2030 (USD Million)
  • Table 9 Mexico Predictive biomarkers market, by indication, 2018 - 2030 (USD Million)
  • Table 10 Mexico Predictive biomarkers market, by technology, 2018 - 2030 (USD Million)
  • Table 11 Europe Predictive biomarkers market, by indication, 2018 - 2030 (USD Million)
  • Table 12 Europe Predictive biomarkers market, by technology, 2018 - 2030 (USD Million)
  • Table 13 UK Predictive biomarkers market, by indication, 2018 - 2030 (USD Million)
  • Table 14 UK Predictive biomarkers market, by technology, 2018 - 2030 (USD Million)
  • Table 15 Germany Predictive biomarkers market, by indication, 2018 - 2030 (USD Million)
  • Table 16 Germany Predictive biomarkers market, by technology, 2018 - 2030 (USD Million)
  • Table 17 France Predictive biomarkers market, by indication, 2018 - 2030 (USD Million)
  • Table 18 France Predictive biomarkers market, by technology, 2018 - 2030 (USD Million)
  • Table 19 Italy Predictive biomarkers market, by indication, 2018 - 2030 (USD Million)
  • Table 20 Italy Predictive biomarkers market, by technology, 2018 - 2030 (USD Million)
  • Table 21 Spain Predictive biomarkers market, by indication, 2018 - 2030 (USD Million)
  • Table 22 Spain Predictive biomarkers market, by technology, 2018 - 2030 (USD Million)
  • Table 23 Denmark Predictive biomarkers market, by indication, 2018 - 2030 (USD Million)
  • Table 24 Denmark Predictive biomarkers market, by technology, 2018 - 2030 (USD Million)
  • Table 25 Sweden Predictive biomarkers market, by indication, 2018 - 2030 (USD Million)
  • Table 26 Sweden Predictive biomarkers market, by technology, 2018 - 2030 (USD Million)
  • Table 27 Norway Predictive biomarkers market, by indication, 2018 - 2030 (USD Million)
  • Table 28 Norway Predictive biomarkers market, by technology, 2018 - 2030 (USD Million)
  • Table 29 Asia Pacific Predictive biomarkers market, by indication, 2018 - 2030 (USD Million)
  • Table 30 Asia Pacific Predictive biomarkers market, by technology, 2018 - 2030 (USD Million)
  • Table 31 Japan Predictive biomarkers market, by indication, 2018 - 2030 (USD Million)
  • Table 32 Japan Predictive biomarkers market, by technology, 2018 - 2030 (USD Million)
  • Table 33 China Predictive biomarkers market, by indication, 2018 - 2030 (USD Million)
  • Table 34 China Predictive biomarkers market, by technology, 2018 - 2030 (USD Million)
  • Table 35 India Predictive biomarkers market, by indication, 2018 - 2030 (USD Million)
  • Table 36 India Predictive biomarkers market, by technology, 2018 - 2030 (USD Million)
  • Table 37 Australia Predictive biomarkers market, by indication, 2018 - 2030 (USD Million)
  • Table 38 Australia Predictive biomarkers market, by technology, 2018 - 2030 (USD Million)
  • Table 39 South Korea Predictive biomarkers market, by indication, 2018 - 2030 (USD Million)
  • Table 40 South Korea Predictive biomarkers market, by technology, 2018 - 2030 (USD Million)
  • Table 41 Thailand Predictive biomarkers market, by indication, 2018 - 2030 (USD Million)
  • Table 42 Thailand Predictive biomarkers market, by technology, 2018 - 2030 (USD Million)
  • Table 43 Latin America Predictive biomarkers market, by indication, 2018 - 2030 (USD Million)
  • Table 44 Latin America Predictive biomarkers market, by technology, 2018 - 2030 (USD Million)
  • Table 45 Brazil Predictive biomarkers market, by indication, 2018 - 2030 (USD Million)
  • Table 46 Brazil Predictive biomarkers market, by technology, 2018 - 2030 (USD Million)
  • Table 47 Argentina Predictive biomarkers market, by indication, 2018 - 2030 (USD Million)
  • Table 48 Argentina Predictive biomarkers market, by technology, 2018 - 2030 (USD Million)
  • Table 49 MEA Predictive biomarkers market, by indication, 2018 - 2030 (USD Million)
  • Table 50 MEA Predictive biomarkers market, by technology, 2018 - 2030 (USD Million)
  • Table 51 South Africa Predictive biomarkers market, by indication, 2018 - 2030 (USD Million)
  • Table 52 South Africa Predictive biomarkers market, by technology, 2018 - 2030 (USD Million)
  • Table 53 Saudi Arabia Predictive biomarkers market, by indication, 2018 - 2030 (USD Million)
  • Table 54 Saudi Arabia Predictive biomarkers market, by technology, 2018 - 2030 (USD Million)
  • Table 55 UAE Predictive biomarkers market, by indication, 2018 - 2030 (USD Million)
  • Table 56 UAE Predictive biomarkers market, by technology, 2018 - 2030 (USD Million)
  • Table 57 Kuwait Predictive biomarkers market, by indication, 2018 - 2030 (USD Million)
  • Table 58 Kuwait Predictive biomarkers market, by technology, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Primary interviews in North America
  • Fig. 5 Primary interviews in Europe
  • Fig. 6 Primary interviews in APAC
  • Fig. 7 Primary interviews in Latin America
  • Fig. 8 Primary interviews in MEA
  • Fig. 9 Market research approaches
  • Fig. 10 Value-chain-based sizing & forecasting
  • Fig. 11 QFD modeling for market share assessment
  • Fig. 12 Market formulation & validation
  • Fig. 13 Predictive biomarkers market: market outlook
  • Fig. 14 Predictive biomarkers competitive insights
  • Fig. 15 Parent market outlook
  • Fig. 16 Related/ancillary market outlook
  • Fig. 17 Penetration and growth prospect mapping
  • Fig. 18 Industry value chain analysis
  • Fig. 19 Predictive biomarkers market driver impact
  • Fig. 20 Predictive biomarkers market restraint impact
  • Fig. 21 Predictive biomarkers market strategic initiatives analysis
  • Fig. 22 Predictive biomarkers market: Indication movement analysis
  • Fig. 23 Predictive biomarkers market: Indication outlook and key takeaways
  • Fig. 24 Cancer market estimates and forecasts, 2018 - 2030
  • Fig. 25 Cardiovascular Diseases market estimates and forecasts,2018 - 2030
  • Fig. 26 Neurological Diseases market estimates and forecasts,2018 - 2030
  • Fig. 27 Immunological Diseases market estimates and forecasts,2018 - 2030
  • Fig. 28 Others market estimates and forecasts,2018 - 2030
  • Fig. 29 Predictive biomarkers market estimates and forecast, 2018 - 2030
  • Fig. 30 Predictive biomarkers Market: Technology movement analysis
  • Fig. 31 Predictive biomarkers market: Technology outlook and key takeaways
  • Fig. 32 Diagnostics market estimates and forecasts, 2018 - 2030
  • Fig. 33 Drug Discovery & Development market estimates and forecasts, 2018 - 2030
  • Fig. 34 Personalized Medicine market estimates and forecasts, 2018 - 2030
  • Fig. 35 Disease Risk Assessment market estimates and forecasts, 2018 - 2030
  • Fig. 36 Others market estimates and forecasts,2018 - 2030
  • Fig. 37 Global Predictive biomarkers market: Regional movement analysis
  • Fig. 38 Global Predictive biomarkers market: Regional outlook and key takeaways
  • Fig. 39 Global Predictive biomarkers market share and leading players
  • Fig. 40 North America market share and leading players
  • Fig. 41 Europe market share and leading players
  • Fig. 42 Asia Pacific market share and leading players
  • Fig. 43 Latin America market share and leading players
  • Fig. 44 Middle East & Africa market share and leading players
  • Fig. 45 North America, by country
  • Fig. 46 North America
  • Fig. 47 North America market estimates and forecasts, 2018 - 2030
  • Fig. 48 U.S.
  • Fig. 49 U.S. market estimates and forecasts, 2018 - 2030
  • Fig. 50 Canada
  • Fig. 51 Canada market estimates and forecasts, 2018 - 2030
  • Fig. 52 Mexico
  • Fig. 53 Mexico market estimates and forecasts, 2018 - 2030
  • Fig. 54 Europe
  • Fig. 55 Europe market estimates and forecasts, 2018 - 2030
  • Fig. 56 UK
  • Fig. 57 UK market estimates and forecasts, 2018 - 2030
  • Fig. 58 Germany
  • Fig. 59 Germany market estimates and forecasts, 2018 - 2030
  • Fig. 60 France
  • Fig. 61 France market estimates and forecasts, 2018 - 2030
  • Fig. 62 Italy
  • Fig. 63 Italy market estimates and forecasts, 2018 - 2030
  • Fig. 64 Spain
  • Fig. 65 Spain market estimates and forecasts, 2018 - 2030
  • Fig. 66 Denmark
  • Fig. 67 Denmark market estimates and forecasts, 2018 - 2030
  • Fig. 68 Sweden
  • Fig. 69 Sweden market estimates and forecasts, 2018 - 2030
  • Fig. 70 Norway
  • Fig. 71 Norway market estimates and forecasts, 2018 - 2030
  • Fig. 72 Asia Pacific
  • Fig. 73 Asia Pacific market estimates and forecasts, 2018 - 2030
  • Fig. 74 China
  • Fig. 75 China market estimates and forecasts, 2018 - 2030
  • Fig. 76 Japan
  • Fig. 77 Japan market estimates and forecasts, 2018 - 2030
  • Fig. 78 India
  • Fig. 79 India market estimates and forecasts, 2018 - 2030
  • Fig. 80 Thailand
  • Fig. 81 Thailand market estimates and forecasts, 2018 - 2030
  • Fig. 82 South Korea
  • Fig. 83 South Korea market estimates and forecasts, 2018 - 2030
  • Fig. 84 Australia
  • Fig. 85 Australia market estimates and forecasts, 2018 - 2030
  • Fig. 86 Latin America
  • Fig. 87 Latin America market estimates and forecasts, 2018 - 2030
  • Fig. 88 Brazil
  • Fig. 89 Brazil market estimates and forecasts, 2018 - 2030
  • Fig. 90 Argentina
  • Fig. 91 Argentina market estimates and forecasts, 2018 - 2030
  • Fig. 92 Middle East and Africa
  • Fig. 93 Middle East and Africa market estimates and forecasts, 2018 - 2030
  • Fig. 94 South Africa
  • Fig. 95 South Africa market estimates and forecasts, 2018 - 2030
  • Fig. 96 Saudi Arabia
  • Fig. 97 Saudi Arabia market estimates and forecasts, 2018 - 2030
  • Fig. 98 UAE
  • Fig. 99 UAE market estimates and forecasts, 2018 - 2030
  • Fig. 100 Kuwait
  • Fig. 101 Kuwait market estimates and forecasts, 2018 - 2030
  • Fig. 102 Market share of key market players - Predictive biomarkers market